Trevi Therapeutics Inc (TRVI) USD0.001
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat neurologically mediated conditions. The Company is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). It is also developing Haduvio in levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. It is conducting a Phase 2b/3 clinical trial of Haduvio in patients with severe pruritus associated with prurigo nodularis. It is also conducting a Phase 2 clinical trial of Haduvio for chronic cough in patients with IPF. It has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus, Pruritus in Chronic Liver Disease and Uremic Pruritus Programs.